Limosilactobacillus reuteri Urob-7 Alleviates Hyperuricemia by Modulating Uric Acid Metabolism Through Nucleoside Degradation and Xanthine Oxidase Inhibition
Foods · 30.10.2025 · 14 (21) · 3706
DOI: 10.3390/foods14213706 ↗Kurz gefasst
Fachartikel in der Zeitschrift Foods, online erschienen am 30.10.2025. Verfasst von Yizhi Jing und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, China Agricultural University, Beijing 100193, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Key R&D Program of China, National Key R&D Program of China.
Abstract (Originalsprache)
Hyperuricemia (HUA), a metabolic disorder characterized by elevated serum uric acid resulting from imbalanced production and excretion, is associated with gout and other serious health issues. This study aimed to screen out the potential probiotics with HUA-alleviating properties among 20 Lactobacillus strains. The results showed that L. reuteri Urob-7 exhibited the highest degradation rates for inosine and guanosine (82.10% and 88.78%, respectively) and strong xanthine oxidase (XOD) inhibitory activity (62.86%). In a HUA mouse model induced by inosine, guanosine, and potassium oxonate, L. reuteri Urob-7 intervention significantly reduced serum uric acid levels by 46.54%, restoring them to levels similar to control groups, and improved kidney function indicators. Moreover, Urob-7 reduced hepatic XOD activity by 37.6% and downregulated XOD expression in the intestines, decreasing excessive uric acid synthesis. It also significantly inhibited the NF-κB/NLRP3 inflammatory pathway, reducing the expression levels of NF-κB and NLRP3 in the kidneys by 39.3% and 47.6%, respectively. Furthermore, L. reuteri Urob-7 increased the abundance of short-chain fatty acid-producing bacteria (e.g., Ruminococcus and Intestinimonas) while reducing the proportion of pathogenic bacteria (e.g., Bacteroides and Anaerovorax), thus ameliorating gut microbiota dysbiosis and intestinal barrier dysfunction. In summary, L. reuteri Urob-7 effectively relieved HUA by modulating uric acid metabolism, suppressing inflammation, and improving gut microbiota balance. These results highlighted its potential as a promising candidate for HUA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, China Agricultural University, Beijing 100193, China.
- College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, China.
- Teaching and Research Division, School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong SAR 999077, China.
ORCID-Profile: Zhengyuan Zhai
Förderung
- The National Key R&D Program of China
- National Key R&D Program of China
Zitieren
APA
Jing, Y., Bai, X., Qian, H., Wang, Y., Hao, Y., Zhai, Z., Zhang, Z., & Hao, Y. (2025). Limosilactobacillus reuteri Urob-7 Alleviates Hyperuricemia by Modulating Uric Acid Metabolism Through Nucleoside Degradation and Xanthine Oxidase Inhibition. Foods, 14(21), 3706. https://doi.org/10.3390/foods14213706
Vancouver
Jing Y, Bai X, Qian H, Wang Y, Hao Y, Zhai Z, et al. Limosilactobacillus reuteri Urob-7 Alleviates Hyperuricemia by Modulating Uric Acid Metabolism Through Nucleoside Degradation and Xanthine Oxidase Inhibition. Foods. 2025;14(21):3706. doi:10.3390/foods14213706
BibTeX
@article{Jing2025,
author = {Jing, Yizhi and Bai, Xiaoyue and Qian, Haidong and Wang, Yue and Hao, Yan and Zhai, Zhengyuan and Zhang, Zhu and Hao, Yanling},
title = {Limosilactobacillus reuteri Urob-7 Alleviates Hyperuricemia by Modulating Uric Acid Metabolism Through Nucleoside Degradation and Xanthine Oxidase Inhibition},
journal = {Foods},
year = {2025},
volume = {14},
number = {21},
pages = {3706},
doi = {10.3390/foods14213706}
}
EUVIMED